These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 31804965

  • 1. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
    Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, Petersenn S, Tauchmanova L, Ravichandran S, Gupta P, Lacroix A, Biller BMK.
    Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
    [Abstract] [Full Text] [Related]

  • 2. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
    Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM.
    Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High variability in baseline urinary free cortisol values in patients with Cushing's disease.
    Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM, Pasireotide B2305 Study Group.
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):261-9. PubMed ID: 23746264
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
    Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T'Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J.
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Accuracy of repeated measurements of late-night salivary cortisol to screen for early-stage recurrence of Cushing's disease following pituitary surgery.
    Danet-Lamasou M, Asselineau J, Perez P, Vivot A, Nunes ML, Loiseau H, San-Galli F, Cherifi-Gatta B, Corcuff JB, Tabarin A.
    Clin Endocrinol (Oxf); 2015 Feb; 82(2):260-6. PubMed ID: 24975391
    [Abstract] [Full Text] [Related]

  • 9. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
    Pivonello R, Fleseriu M, Newell-Price J, Shimatsu A, Feelders RA, Kadioglu P, Tabarin A, Brue TC, Geer EB, Piacentini A, Pedroncelli AM, Biller BMK.
    J Endocrinol Invest; 2024 Oct; 47(10):2437-2448. PubMed ID: 38696122
    [Abstract] [Full Text] [Related]

  • 10. Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests.
    Alwani RA, Schmit Jongbloed LW, de Jong FH, van der Lely AJ, de Herder WW, Feelders RA.
    Eur J Endocrinol; 2014 Apr; 170(4):477-86. PubMed ID: 24394725
    [Abstract] [Full Text] [Related]

  • 11. A 12-month phase 3 study of pasireotide in Cushing's disease.
    Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group.
    N Engl J Med; 2012 Mar 08; 366(10):914-24. PubMed ID: 22397653
    [Abstract] [Full Text] [Related]

  • 12. POSTSURGICAL RECURRENT CUSHING DISEASE: CLINICAL BENEFIT OF EARLY INTERVENTION IN PATIENTS WITH NORMAL URINARY FREE CORTISOL.
    Carroll TB, Javorsky BR, Findling JW.
    Endocr Pract; 2016 Oct 08; 22(10):1216-1223. PubMed ID: 27409817
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
    Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF, Feelders RA, Heaney AP, Paul M, Pedroncelli AM, Auchus RJ.
    Front Endocrinol (Lausanne); 2023 Oct 08; 14():1236465. PubMed ID: 37680892
    [Abstract] [Full Text] [Related]

  • 14. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
    Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R, Pasireotide B2305 Study Group.
    Pituitary; 2015 Oct 08; 18(5):604-12. PubMed ID: 25537481
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
    Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.
    Eur J Endocrinol; 2014 Jul 08; 171(1):89-98. PubMed ID: 24760537
    [Abstract] [Full Text] [Related]

  • 17. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BM.
    J Clin Endocrinol Metab; 2014 Apr 08; 99(4):1375-83. PubMed ID: 24423285
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of cyclic Cushing's disease using late night salivary cortisol testing.
    Jahandideh D, Swearingen B, Nachtigall LB, Klibanski A, Biller BMK, Tritos NA.
    Clin Endocrinol (Oxf); 2018 Sep 08; 89(3):336-345. PubMed ID: 29873834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.